secwatch.observer — SEC 8-K summary
======================================

Issuer:     IO Biotech, Inc. (IOBTQ)
CIK:        0001865494
Form:       8-K
Filed at:   2022-05-16T23:59:59+00:00
Accession:  0001193125-22-151812
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IO Biotech Q1 2022 net loss $17.2M; cash $187.9M; Phase 2 trial initiated
-------------------------------------------------------------------------

- Net loss of $17.2M for Q1 2022 vs $3.7M in Q1 2021; R&D expenses $10.3M (up $7.5M).
- Cash and equivalents $187.9M at March 31, 2022, down from $211.5M at Dec 31, 2021; runway to mid-2024.
- Initiated Phase 2 trial (IOB-022/KN-D38) of IO102-IO103 with pembrolizumab in first-line treatment.
- Updated Phase 1/2 data for IO102-IO103 + nivolumab in metastatic melanoma showed 73% 3-year survival probability.
- Phase 3 trial (IOB-013/KN-D18) with Merck ongoing; guidance on interim readout timing expected mid-2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1865494/000119312522151812/0001193125-22-151812-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1865494/000119312522151812/d334702d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-151812

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer